Stockreport

Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade) [Seeking Alpha]

Organon & Co.  (OGN) 
PDF Summary In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon repo [Read more]